Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:30:03 01/06/2024 am IST			5-day change	1st Jan Change
1.4 ^USD	+6.06%		-6.67%	+248.26%

24/05	Perspective Therapeutics Prices $80 Million Share, Warrant Offering	MT
15/05	Transcript : Perspective Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM

Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 15, 2024 at 04:30 pm IST

Perspective Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 12.28 million compared to USD 0.371 million a year ago.

Latest news about Perspective Therapeutics, Inc.

Perspective Therapeutics Prices $80 Million Share, Warrant Offering	24/05	MT
Transcript : Perspective Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM	15/05
Perspective Therapeutics Swings to Loss in Q1, Revenue Rises	15/05	MT
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
RBC Starts Perspective Therapeutics With Outperform Rating, $3 Price Target	14/05	MT
Cantor Fitzgerald Starts Perspective Therapeutics With Overweight Rating	09/05	MT
Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry	30/04	CI
Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	18/04	CI
Certain Warrants of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	18/04	CI
Certain Stock Options of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	18/04	CI
B. Riley Raises Price Target on Perspective Therapeutics to $1.70 From $1.20, Maintains Buy Rating	09/04	MT
Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.50 From $1.20, Maintains Outperform Rating	01/04	MT
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
North American Morning Briefing : Markets Steady -2-	26/03	DJ
North American Morning Briefing : Stock Futures -2-	19/03	DJ
Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study	18/03	MT
Transcript : Perspective Therapeutics, Inc. - Analyst/Investor Day	18/03
Perspective Therapeutics, Inc. Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb)VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma	18/03	CI
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. and other investors	06/03	CI
Sector Update: Health Care Stocks Softer in Afternoon Trading	05/03	MT
Perspective Therapeutics to Raise $87.4 Million in Private Placement	04/03	MT
Perspective Therapeutics, Inc. completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.	01/03	CI
Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform	01/02	CI
B. Riley Starts Perspective Therapeutics With Buy Rating, $1.20 Price Target; Says Well-Positioned to Break Out of Biotech Pack	26/01	MT
Perspective Therapeutics Closes $89.8 Million Public Offering, Concurrent Private Placement	23/01	MT

Chart Perspective Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-Î±-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

Sector

Biotechnology & Medical Research

Calendar

09/06/2024 - Society of Nuclear Medicine and Molecular Imaging Meeting - Abstract No - 241158

More about the company

Income Statement Evolution

More financial data

Ratings for Perspective Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.38 USD

Average target price

2.26 USD

Spread / Average Target

+63.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PERSPECTIVE THERAPEUTICS, INC.	+248.26%	930M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research